TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA expanded remibrutinib’s indication to include adults with symptomatic dermographism whose symptoms are inadequately controlled by H1 antihistamines. In a phase III trial cohort, complete response at 12 weeks was reported in 29.3% of patients receiving remibrutinib and 14.0% receiving placebo.
The FDA has expanded remibrutinib’s approved use to include adults with symptomatic dermographism whose condition is inadequately controlled by H1 antihistamines, Novartis announced. The decision adds a prescription treatment option for a form of chronic inducible urticaria, or hives triggered by specific physical stimuli.
The approval is based principally on the symptomatic dermographism cohort of the phase III RemIND trial. Participants had chronic inducible urticaria that remained symptomatic despite treatment with second-generation H1 antihistamines. The trial compared oral remibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, with placebo.
At 12 weeks, 29.3% of participants taking remibrutinib met the trial’s criteria for complete response, compared with 14.0% in the placebo group, based on the Total Fric Score. The reported difference had a P value of 0.0229. Novartis said responses were observed as early as two weeks after treatment began; that timing does not establish that all patients respond that quickly.
The company reported that remibrutinib had a consistent safety profile in clinical trials with follow-up to 24 weeks. Adverse events reported in at least 3% of patients included nasal congestion, sore throat, nasopharyngitis, bleeding, headache, nausea and abdominal pain. The available report does not provide event rates for each side effect or a detailed comparison with placebo.
A New Option After Antihistamines
The expanded indication gives eligible adults with symptomatic dermographism another prescription treatment option when H1 antihistamines have not adequately controlled symptoms. The reported trial results suggest remibrutinib increased the proportion of participants reaching complete response at 12 weeks compared with placebo, though most participants in the remibrutinib group did not meet that endpoint during the reported period.
Novartis described remibrutinib as the first prescription drug approved for both chronic spontaneous urticaria and symptomatic dermographism. The company said the two conditions together occur in more than 90% of patients with chronic hives. That figure is a company-provided estimate in the report, and the article does not specify its underlying source or method.
The approval concerns a specific group: adults with symptomatic dermographism inadequately controlled by H1 antihistamines. It does not, based on the information available, establish a benefit for every person with hives or replace individual clinical assessment.
How RemIND Supported the Approval
Symptomatic dermographism is described in the report as the most common form of chronic inducible urticaria. In this condition, physical friction or pressure can bring on symptoms. Chronic inducible urticaria differs from chronic spontaneous urticaria, in which hives occur without a consistent external trigger.
The RemIND trial enrolled people whose symptoms persisted despite second-generation H1 antihistamines. Its reported result for this approval came from the symptomatic dermographism cohort, rather than from all patients with chronic urticaria. The outcome cited was complete response measured using the Total Fric Score at 12 weeks.
Before the expanded indication, remibrutinib was approved for chronic spontaneous urticaria, according to Novartis’ announcement. The FDA action extends the drug’s labeled use to another urticaria condition; it does not mean that the two conditions have identical triggers or treatment responses.
Questions on Use and Longer-Term Safety
The available report does not include the full FDA prescribing information, dosing instructions, contraindications or detailed trial results beyond the 12-week complete-response figures. It also does not specify how many participants were in the dermographism cohort or provide confidence intervals and detailed adverse-event rates. Those details are needed to assess the size and limits of the evidence more fully.
Safety follow-up in the reported trials extended to 24 weeks; the source material does not describe longer-term outcomes. It is also unclear from the report how remibrutinib compares directly with other treatment approaches, or which patients are most likely to benefit. The approval applies to adults meeting the stated indication, and treatment decisions should be based on the full label and a clinician’s assessment.
Prescribing Details and Patient Discussions
Clinicians and patients can refer to the FDA-approved prescribing information for the authorized dose, warnings and guidance on monitoring. The announcement does not give a timeline for additional trial analyses or longer-term follow-up. Further published data could clarify how durable responses are and how safety findings develop beyond the reported 24-week period.
For adults with symptoms that remain inadequately controlled by H1 antihistamines, the next step is a discussion with a healthcare professional about whether the newly approved option is appropriate. The trial figures describe group outcomes and cannot predict an individual patient’s response.
Key Questions
What did the FDA approve?
The FDA expanded remibrutinib’s indication to include adults with symptomatic dermographism whose condition is inadequately controlled by H1 antihistamines.
What were the phase III trial results?
At 12 weeks, 29.3% of participants receiving remibrutinib met the complete-response criteria based on the Total Fric Score, compared with 14.0% receiving placebo. The figures are for the symptomatic dermographism cohort reported in the source material.
How soon were responses observed?
Novartis said responses were observed as early as two weeks after treatment began. The report does not say that every patient responded by that point.
What side effects were reported?
Adverse events occurring in at least 3% of patients included nasal congestion, sore throat, nasopharyngitis, bleeding, headache, nausea and abdominal pain. The report says the safety profile was consistent in trials with follow-up to 24 weeks, but does not give individual event rates.
Does the approval apply to everyone with chronic hives?
No. The stated indication is for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. Patients should consult a healthcare professional about whether the treatment fits their diagnosis and circumstances.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
